JPWO2022081486A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022081486A5 JPWO2022081486A5 JP2023521532A JP2023521532A JPWO2022081486A5 JP WO2022081486 A5 JPWO2022081486 A5 JP WO2022081486A5 JP 2023521532 A JP2023521532 A JP 2023521532A JP 2023521532 A JP2023521532 A JP 2023521532A JP WO2022081486 A5 JPWO2022081486 A5 JP WO2022081486A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- acid sequence
- amino acid
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 62
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 44
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000001177 retroviral effect Effects 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims description 2
- 210000005059 placental tissue Anatomy 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 241001663880 Gammaretrovirus Species 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063090440P | 2020-10-12 | 2020-10-12 | |
| US63/090,440 | 2020-10-12 | ||
| PCT/US2021/054437 WO2022081486A1 (en) | 2020-10-12 | 2021-10-11 | Cd19-directed chimeric antigen receptor constructs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544836A JP2023544836A (ja) | 2023-10-25 |
| JP2023544836A5 JP2023544836A5 (https=) | 2024-10-16 |
| JPWO2022081486A5 true JPWO2022081486A5 (https=) | 2024-10-16 |
Family
ID=81209376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521532A Pending JP2023544836A (ja) | 2020-10-12 | 2021-10-11 | Ｃｄ１９に指向されたキメラ抗原受容体構築物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240261330A1 (https=) |
| EP (1) | EP4225799A4 (https=) |
| JP (1) | JP2023544836A (https=) |
| CN (1) | CN116601174A (https=) |
| WO (1) | WO2022081486A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4724492A1 (en) * | 2023-06-09 | 2026-04-15 | Antengene Biologics Limited | Novel antibodies targeting cd3 and another target and uses thereof |
| WO2026020171A2 (en) | 2024-07-19 | 2026-01-22 | Aera Therapeutics, Inc. | Chimeric antigen receptor constructs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US10875919B2 (en) * | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
| CA3125751A1 (en) * | 2019-01-07 | 2020-07-16 | Magenta Therapeutics, Inc. | Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy |
| AU2020232691B2 (en) * | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| RU2742000C2 (ru) * | 2019-03-13 | 2021-02-01 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
-
2021
- 2021-10-11 WO PCT/US2021/054437 patent/WO2022081486A1/en not_active Ceased
- 2021-10-11 US US18/248,079 patent/US20240261330A1/en active Pending
- 2021-10-11 CN CN202180083392.0A patent/CN116601174A/zh active Pending
- 2021-10-11 EP EP21880858.2A patent/EP4225799A4/en not_active Withdrawn
- 2021-10-11 JP JP2023521532A patent/JP2023544836A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7767549B2 (ja) | Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定 | |
| JP2021177771A5 (https=) | ||
| JP2022025086A5 (https=) | ||
| AU2019218989B2 (en) | Chimeric antigen receptors targeting the tumor microenvironment | |
| JP2024522357A (ja) | クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 | |
| JP6633081B2 (ja) | 細胞 | |
| JP2021525524A5 (https=) | ||
| Dreier et al. | Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody | |
| CN109824778B (zh) | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| JP2021515558A5 (https=) | ||
| JP2010513306A5 (https=) | ||
| JPWO2019215500A5 (https=) | ||
| RU2017134652A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 | |
| JPWO2020069028A5 (https=) | ||
| KR20170122258A (ko) | Ｃｄ20 결합 분자 및 그의 용도 | |
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| CN112689642B (zh) | 具有各种不同的构建物优化的t细胞抗原偶联物 | |
| CN108395481B (zh) | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 | |
| CN111479925A (zh) | 具有y182t突变的t细胞-抗原偶联物及其方法和用途 | |
| JP2022539587A (ja) | Ｂ細胞悪性腫瘍の処置のために細胞表面マーカーｃｄ７２を標的とする免疫療法 | |
| JP2020510074A5 (https=) | ||
| JPWO2019173837A5 (https=) | ||
| JPWO2022081486A5 (https=) | ||
| WO2023196932A2 (en) | Isolating active t-cell cars from bulk transduced human t-cells |